Search | Clinical Trials Finder

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: cholecalciferol; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
Interventions: Bone Marrow Biopsy, Epoetin Alfa, Laboratory Biomarker Analysis, Lenalidomide; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 507
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 345 more

Conditions: Myelodysplastic Syndrome, Aplastic Anemia
Interventions: Thymoglobulin, Cyclosporine, Methylprednisolone, G-CSF; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions: Venetoclax, Decitabine; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Sacramento, California • The Bronx, New York • White Plains, New York

Conditions: Leukemia
Interventions: Alemtuzumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: Luspatercept, Epoetin Alfa; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 33
States / cities: Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: Myeloma, Plasma-Cell, Lymphoma, Malignant, Myeloproliferative Disorders, Myelodysplastic Syndromes, Waldenstrom's Macroglobulinemia
Interventions: Reduced intensity conditioning with allogeneic transplant; Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
Interventions: Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Tacrolimus; Drug · Procedure
Lead sponsor: Hannah Choe, MD; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio

Conditions: Leukemia
Interventions: Bortezomib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
Interventions: Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, Methylprednisolone, Pegfilgrastim; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: Omacetaxine, Cytarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: ARRY-614, p38/Tie2 inhibitor; oral; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Tampa, Florida • Atlanta, Georgia • Cleveland, Ohio + 1 more

Conditions: Myelodysplastic Syndrome
Interventions: Erythropoietin, Cyclosporin A, G-CSF, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: Oral rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 10
States / cities: Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions: iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis; Radiation · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 16 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Myelodysplastic Syndromes, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Houston, Texas

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: PD-616; Drug
Lead sponsor: Biosuccess Biotech Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Duarte, California • Lexington, Kentucky

Conditions: Leukemia
Interventions: Ruxolitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC), Azacitidine (AZA) Days 1 - 5; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 6
States / cities: Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML)
Interventions: low dose 5'-azacitidine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Myelodysplastic Syndrome With Isolated Del(5q), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia
Interventions: clofarabine, cytarabine; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Myelodysplastic Syndrome
Interventions: LBH589; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more

Search by objective public record fields.

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)